August 29, 2018


Media & events


Lyndra, Inc. and Allergan Sign a Partnership to Develop Ultra-Long-Acting Oral Products

September 7, 2017
Companies will collaborate to create products dosed once-weekly for the treatment of Alzheimer’s disease. Lyndra, Inc. (Lyndra) announced today a...
Read More



Lyndra Named as Scrip Award Finalist in Two Categories

Happy to announce our ultra-long acting oral dosage form has been named a finalist for the Scrip MSD Innovation Award, and our co-founder Amy Schulman has been named a finalist in the Executive of the Year category!


Amy Schulman, Lyndra Co-founder and CEO, honored on 2019 PharmaVOICE 100

“Amy’s fearless approach to create durable value and change the trajectory of compliance for some of most difficult to treat diseases —  Alzheimer’s disease, HIV, opioid use disorder, and schizophrenia — are just a couple of the reasons she has been identified as one of the 100 most inspiring people in the life-sciences industry,” says Taren Grom, editor, PharmaVOICE


2019 Xconomy Awards Finalist in Startup Category

We are honored to be named a finalist for the Awards in the category for our work making daily pills a thing of the past.



Lyndra Presents @ BIO International

Join us on Thursday, June 5th, at 5pm when Andrew Bellinger, our CSO, presents our 2019 Company Update at BIO International, Philadelphia Convention Center, Theater 4

2019 BIO International